anti-human CCL-22 monoclonal antibody Anti-Human 100 µg,Reliatech,101-M266

This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with human recombinant protein of CCL-22 (also called MDC).

Host

Mouse

Reactivity

Human

Application

WB, N

Platform ID

BAB933566370

Reliatech

Headquarters

Lindener Straße 15 38300 Wolfenbüttel Germany

Contact

Tel: +49 (0) 5331 - 8586987
Fax: +49 (0) 5331- 8586989

Product Specifications
Scientific Background
Synonyms

Specifications

Nameanti-human CCL-22 monoclonal antibody Anti-Human 100 µg
Cat. No.101-M266
Accession NumberO00626
HostMouse
IsotypeIgG2
ReactivityHuman
ApplicationWB, N
Clone Number(#13G44)
Appearance/Formlyophilized
FormulationPBS
ReconstitutionCentrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml.
StorageLyophilized samples are stable for 2 years from date of receipt when stored at -70°C. Reconstituted antibody can be aliquoted and stored frozen at < -20°C for at least six months without detectable loss of activity.
Regulatory StatusFor research use only

Scientific Background

CCL22, also named stimulated T cell chemotactic protein (STCP1) and MDC, is a CC chemokine initially isolated from clones of monocytederived macrophages. Human CCL22 cDNA encodes a precursor protein of 93 amino acid residues with a 24 amino acid residue predicted signal peptide that is cleaved to yield a 69 amino acid residue mature 8 kDa protein. At the amino acid sequence level, CCL22 shows less than 35% identity to other CC chemokine family members. Human CCL22 is expressed in dendritic cells, macrophages and activated monocytes. In addition, CCL22 expression is also detected in the tissues of thymus, lymph node and appendix. The gene for human CCL22 has been mapped to chromosome 16 rather than chromosome 17 where the genes for many human CC chemokines are clustered. Recombinant or chemically synthesized mature CCL22 has been shown to induce chemotaxis or Ca2+ mobilization in dendritic cells, IL2 activated NK cells, and activated T lymphocytes. A CD8+ T lymphocytederived secreted soluble activity that suppresses infection by primary non-syncytium-inducing and syncytium-inducing HIV1 isolates and the T cell lineadapted isolate HIV1 IIIB, has been identified as CCL22. Based on aminoterminal sequence analysis, the major CD8 + T lymphocyte-derived CCL22 protein yielded an amino-terminal sequence of YGANM, which is two amino acid residues shorter than the predicted mature CCL22. The difference in potency between the two mature CCL22 isoforms has not been determined.

Synonyms

CCL22; MDC; ABCD-1; SCYA22; STCP-1; DC/B-CK; A-152E5.1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.